☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
nasopharyngeal carcinoma
Junshi and Coherus Report the US FDA Acceptance of BLA for Toripalimab to Treat Nasopharyngeal Carcinoma
November 2, 2021
Junshi and Coherus's Toripalimab Receive the US FDA's Breakthrough Therapy Designation as 1L Treatment of Nasopharyngeal Carcinoma
August 13, 2021
Junshi Reports Results of Dual Regimen in P-III Jupiter-02 Study as 1L Therapy for Nasopharyngeal Carcinoma
September 30, 2020
Junshi's Toripalimab Receives the US FDA's Breakthrough Therapy Designation for the Treatment of Nasopharyngeal Carcinoma
September 10, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.